Loomis, Sayles & Company
ANIK icon

Loomis, Sayles & Company’s Anika Therapeutics ANIK Stock Holding History

Loomis, Sayles & Company’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-79
Closed -$4K – 874
2018
Q1 		$4K Hold
79
– – ﹤0.01% 857
2017
Q4 		$4K Hold
79
– – ﹤0.01% 832
2017
Q3 		$5K Hold
79
– – ﹤0.01% 840
2017
Q2 		$4K Hold
79
– – ﹤0.01% 872
2017
Q1 		$3K Hold
79
– – ﹤0.01% 897
2016
Q4 		$4K Hold
79
– – ﹤0.01% 917
2016
Q3 		$4K Hold
79
– – ﹤0.01% 903
2016
Q2 		$4K Buy
+79
New +$3.72K ﹤0.01% 874
2015
Q4 		– Sell
-198
Closed -$6K – 1044
2015
Q3 		$6K Hold
198
– – ﹤0.01% 933
2015
Q2 		$7K Buy
+198
New +$7.06K ﹤0.01% 840

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Loomis, Sayles & Company's ANIK Position: Q2 2018 in Review

Loomis, Sayles & Company sold out of Anika Therapeutics (ANIK) in Q2 2018, closing a stake of 79 shares — an estimated $4K sold.

Loomis, Sayles & Company first reported a position in ANIK in Q2 2015 and held it in 10 quarters. The position peaked at $7K in Q2 2015. 170 funds tracked by Wall St. Rank hold ANIK as of Q2 2018.

  • Loomis, Sayles & Company reported no remaining Anika Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Loomis, Sayles & Company sold 79 Anika Therapeutics shares in Q2 2018, an estimated $4K.
  • Loomis, Sayles & Company first reported a position in Anika Therapeutics in Q2 2015 and held it in 10 quarters.
  • Loomis, Sayles & Company's Anika Therapeutics position peaked at $7K in Q2 2015.
  • 170 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2018.

Based on Loomis, Sayles & Company's 13F filing for Q2 2018, filed 14 Aug 2018.